16mg retatrutide – NewBioRx Retatrutide Phase 3: 60% Achieved
Description
Is there any reason why treating obesity shouldnt involve a similar approach
Placebo-controlled trial showing subcutaneous semaglutide treatment resulted in a higher percentage of NASH resolution in NASH patients than placebo
Patients taking a placebo experienced a reduction of less than 10%
There were also differences in reported GLP-1RA use in different races
For these variables, the normal distribution was obtained after log transformation
GLP-1 works best as support for healthier eating and regular movement, not as a replacement for them
